Osteoporosis medications

00:00 / 00:00

Flashcards

Osteoporosis medications

de completadas

Preguntas

Preguntas del estilo USMLE Step 1

de completadas

Preguntas del estilo USMLE Step 2

de completadas

A 60-year-old woman comes to her primary care physician for a wellness checkup. The patient recently had a dual-energy X-ray absorptiometry (DEXA) scan that placed her at two standard deviations below the mean for bone density and is following up today to discuss the results. Past medical history is notable for asthma, anxiety, irritable bowel syndrome, and radial fracture that occurred 5-months ago following a ground-level fall. Current medications include clonazepam and albuterol. Vitals are within normal limits. The patient is started on raloxifene in addition to weight-bearing exercise and vitamins. This patient is at increased risk of developing which of the following?  

External References

First Aid

2024

2023

2022

2021

Alendronate p. 495

Transcript

Watch video only

Osteoporosis medications are medications used to treat osteoporosis, which is a condition where decreased bone strength increases the risk of a broken bone.

Osteoporosis is most commonly associated with the elderly, menopause, hyperparathyroidism, malabsorption, and with the use of some medications, like corticosteroids.

So, the underlying cause of osteoporosis is an imbalance between bone resorption and bone formation, which are normal processes of bone remodeling.

Now in bone remodeling, the process begins when osteoblasts sense micro fractures near their location.

The osteoblasts produce a substance called RANKL, or receptor activator of nuclear factor κβ ligand, which binds to RANK receptors on the surface of nearby monocytes.

RANKL induces those monocytes to fuse together to form a multinucleated osteoclast cell.

RANKL also helps the osteoclast mature and activate so that they can start resorbing bones.

The osteoclast starts secreting lysosomal enzymes, mostly collagenase, which digests the collagen protein in the organic matrix. This drills pits on the bone surface known as the Howship’s lacunae.

Osteoclasts also start producing hydrochloric acid, or HCl, which dissolves hydroxyapatite into soluble calcium – Ca2+ and phosphate – PO42- ions, and these ions get released into the bloodstream.

Moreover, osteoblasts and osteoclasts are controlled by two hormones: parathyroid hormone, which is released by parathyroid glands; and calcitonin, which is released by the thyroid gland.

At low concentrations, parathyroid hormone works by stimulating the activity of osteoblasts, thereby promoting bone formation; while at high concentrations, parathyroid hormone stimulates bone resorption.

On the other hand, calcitonin works by inhibiting osteoclast activity, thereby decreasing bone resorption.

Alright, moving on to pharmacology! Osteoporosis medications are subdivided into two main groups: non-hormonal medications, which include bisphosphonates and denosumab; and hormonal modulators, which include teriparatide, calcitonin, and raloxifene.

Fuentes

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Teriparatide for osteoporosis: importance of the full course" Osteoporosis International (2016)
  5. "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline" The Journal of Clinical Endocrinology & Metabolism (2019)
  6. "Osteoporosis" Clin Orthop Relat Res (2000)
  7. "Bisphosphonates" Endocrinol Metab Clin North Am (2003)
  8. "Understanding bisphosphonates and osteonecrosis of the jaw: uses and risks" Eur Rev Med Pharmacol Sci (2015)
  9. "Pharmacology of bisphosphonates" Bone (2011)
  10. "Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures" Asia Pac J Clin Oncol (2017)
  11. "Author Correction to: Denosumab: A Review in Postmenopausal Osteoporosis" Drugs Aging (2018)
Elsevier

Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.

RELX